CA2277724C - Composition destinee a provoquer une anergie humorale a un immunogene
- Google Patents
Composition destinee a provoquer une anergie humorale a un immunogene
Download PDF
Info
Publication number
CA2277724C
CA2277724CCA002277724ACA2277724ACA2277724CCA 2277724 CCA2277724 CCA 2277724CCA 002277724 ACA002277724 ACA 002277724ACA 2277724 ACA2277724 ACA 2277724ACA 2277724 CCA2277724 CCA 2277724C
Authority
CA
Canada
Prior art keywords
immunogen
conjugate
cell
conjugate according
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/652,648external-prioritypatent/US5268454A/en
Application filed by La Jolla Pharmaceutical CofiledCriticalLa Jolla Pharmaceutical Co
Publication of CA2277724A1publicationCriticalpatent/CA2277724A1/fr
Application grantedgrantedCritical
Publication of CA2277724CpublicationCriticalpatent/CA2277724C/fr
Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
Procede de synthese regulee par etapes d'especes chimiques, notamment de peptides, de produits couples obtenus selon le procede, et emploi de ces produits couples, par exemple en tant que vaccins
Immune recognition of serum albumin. 15: Localization by Synthesis of antigenic Site 4 of bovine serum albumin to theregion around the disulfide bond 166–175
Immunoglobulines anti-peptidiques pour des épitopes de glycoprotéine de spicule de coronavirus de syndrome respiratoire aigu sévère 2 (sras-cov -2) et immunogènes apparentés, procédé de production et d'utilisation de ceux-ci, et systèmes de détection d'antigène associés à ceux-ci